CLINICAL_TRIALS ClinicalTrials.gov record update

Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary: A Prospective, Open-label, Single-arm Clinical Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05241132
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:47.865160+00:00
Published At: 2022-02-15T00:00:00+00:00
Record Updated At: 2022-02-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Cancer of Unknown Primary", "Bone Cancer Metastatic", "Tislelizumab", "Gene Mutation-Related Cancer", "Immune Evasion, Tumor", "Chemotherapy Effect"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-02-15"
protocolSection.identificationModule.nctId: "NCT05241132"
protocolSection.identificationModule.officialTitle: "Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary: A Prospective, Open-label, Single-arm Clinical Study"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.